GENOTYPE OR PHENOTYPE - THE DEFINITION OF A PHARMACOGENETIC POLYMORPHISM

被引:43
作者
MEYER, UA
机构
[1] Biocenter of the University of Basel, Department of Pharmacology, Basel, CH-4056
来源
PHARMACOGENETICS | 1991年 / 1卷 / 02期
关键词
D O I
10.1097/00008571-199111000-00002
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
[No abstract available]
引用
收藏
页码:66 / 67
页数:2
相关论文
共 8 条
[1]  
Antonarakis S.E., Diagnosis of genetic disorders at the DNA level, New Engl J Med, 320, pp. 153-163, (1989)
[2]  
Arias T.D., Jorge L.F., Barrantes R., Uses and misuses of definition of genetic polymorphism. A perspective from population pharmacogenetics, Br J Clin Pharmacol, 31, pp. 117-119, (1991)
[3]  
Cavalli-Sforza L.L., Bodmer W.F., The Genetics of Human Populations, (1971)
[4]  
Ford E.B., Polymorphism and taxonomy, The New Systematics, pp. 493-573, (1940)
[5]  
Harris H., Principles of Human Biochemical Genetics, (1980)
[6]  
Meyer U.A., Skoda R.C., Zanger U.M., The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms, Pharmacol Ther, 46, pp. 297-308, (1990)
[7]  
Skoda R.C., Gonzalez F.J., Demierre A., Meyer U.A., Two mutant alleles of the human cytochrome P450 dbl gene (P450 C2D1) associated with genetically deficient metabolism of debriso- quine and other drugs, Proc Natl Acad Sci USA, 85, pp. 5240-5243, (1988)
[8]  
Vogel F., Motulsky A.G., Human Genetics, Problems and Approaches, (1986)